Quarterly report pursuant to Section 13 or 15(d)

Other current assets

v3.20.2
Other current assets
6 Months Ended
Jun. 30, 2020
Other current assets  
Other current assets

Note 8 — Other current assets

Other current assets consisted of the following (in thousands):

June 30, 

December 31, 

    

2020

    

2019

Corporate tax receivable

 

$

26,746

 

$

19,284

Prepayments

 

7,903

 

8,395

Clinical materials

 

1,521

 

1,459

Other current assets

 

2,929

 

1,809

$

39,099

$

30,947

In July 2020, the Company received $18.7 million of the above Corporate tax receivable balance, reimbursable Research & Development Tax Credits relating to the previous financial year included within Corporate tax receivable as of June 30, 2020. The remainder of the Corporate tax receivable balance above relates to 2020.